CONNECT WITH US
HealthTech

HealthTech

Abbott starts trial of Encantor transcatheter aortic valve

MedTech Dive logo

Published on

Add as a preferred source on Google
Abbott starts trial of Encantor transcatheter aortic valve

Physicians treating symptomatic severe aortic stenosis have access to balloon- and self-expanding valves. Edwards Lifesciences’ Sapien valves use a balloon-expandable frame, while Medtronic’s Evolut devices are self-expanding. The Food and Drug Administration approved Abbott’s self-expanding Navitor valve in 2023.

“Physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients,” Didier Tchétché, a physician and co-principal investigator of Abbott’s trial, said in a statement. “Encantor’s balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence.”

Encantor crimps the new heart valve on a deflated surgical balloon, which is inserted into the body via a catheter in a groin artery. Once the balloon reaches the diseased aortic valve in the heart, the physician customizes the valve’s expansion to the patient’s anatomy using software-guided deployment. The balloon is then deflated and removed, leaving the replacement valve in place.

Macquarie University in Sydney, Australia, recently enrolled the first patient in VOYAGER CE. Abbott is running the single-arm study to assess Encantor’s effect on the number of deaths and strokes in the 12 months after treatment. The company plans to use the results to seek approval for the device in Europe and Australia.

Abbott began VOYAGER CE after seeing six-month results from an early feasibility study of the device. The company will share the data on Encantor at PCR London Valves 2026, which begins on Sunday.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.